Teva Pharmaceutical Industries Ltd (TEVA)

TEVA (NYSE:Drugs) EQUITY
$54.45
pos +0.00
+0.00%
Today's Range: 54.01 - 55.31 | TEVA Avg Daily Volume: 5,678,900
Last Update: 04/29/16 - 4:01 PM EDT
Volume: 0
YTD Performance: -17.05%
Open: $0.00
Previous Close: $54.99
52 Week Range: $52.62 - $72.31
Oustanding Shares: 907,663,041
Market Cap: 49,912,390,625
6-Month Chart
TheStreet Ratings Grade for TEVA
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 12 12 12 11
Moderate Buy 2 2 2 2
Hold 4 4 4 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.53 1.53 1.53 1.56
Latest Dividend: 0.29
Latest Dividend Yield: 2.10%
Dividend Ex-Date: 02/25/16
Price Earnings Ratio: 30.21
Price Earnings Comparisons:
TEVA Sector Avg. S&P 500
30.21 30.20 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-11.43% -12.29% 40.55%
GROWTH 12 Mo 3 Yr CAGR
Revenue -3.10 0.00 -0.01
Net Income -47.50 -0.20 -0.06
EPS -48.90 -0.20 -0.06
Earnings for TEVA:
EBITDA 5.79B
Revenue 19.65B
Average Earnings Estimates
Qtr (03/16) Qtr (06/16) FY (12/16) FY (12/17)
Average Estimate $1.13 $1.21 $5.23 $5.74
Number of Analysts 3 3 6 6
High Estimate $1.16 $1.31 $5.66 $6.37
Low Estimate $1.07 $1.15 $4.64 $4.64
Prior Year $1.36 $1.43 $5.42 $5.23
Growth Rate (Year over Year) -17.16% -15.15% -3.51% 9.78%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Inovio Pharmaceuticals and Eagle Pharmaceuticals both boast solid pipelines and sound balance sheets.
Candidates have decried rising drug and medical prices, but there are reasons to like these stocks.
After the thwarted Pfizer merger, the generic drug business sale will supply plenty of "ammo."
After the thwarted Pfizer merger, the generic drug business sale will supply plenty of "ammo."
A research note confirms that its generics sale to Teva will go ahead.
I'm focused more on the secondary technicals here rather than the price.
CEO Read says the Viagra maker retains the means to pursue 'attractive business development' opportunities as he tears up the six-month-old deal with the maker of Botox.
Downgrades and Allergan's government woes could have inspired panic, but that didn't happen, and that's a sign of strength.

Columnist Conversations

Mine and many other reviews of the meeting coming Monday, but the quick highlights to whet your appetite: 1)...
Up in an hour or so! Enjoy your weekend and thanks for reading my Diary.
HIG
HIG, the object of my affection today, rips +$0.50 higher in the last few minutes of trading. Just wishing and...
Rolling SDS long sale proceeds into SPY/QQQ $2.5 billion to buy at month end, aiding markets. Trying to be opp...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.